A phase 1 study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 7 days every 21 days in pediatric patients with solid tumors. (Q40472146)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A phase 1 study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 7 days every 21 days in pediatric patients with solid tumors. |
scientific article |
Statements
1 reference
A phase 1 study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 7 days every 21 days in pediatric patients with solid tumors. (English)
1 reference
John M Maris
1 reference
Elizabeth Fox
1 reference
Brigitte C Widemann
1 reference
Kysa Meek
1 reference
Anne Goodwin
1 reference
Wendy Goodspeed
1 reference
Marie Kromplewski
1 reference
Molly E Fouts
1 reference
Diane Medina
1 reference
Steve Y Cho
1 reference
Andrew Krivoshik
1 reference
Anne E Hagey
1 reference
Peter C Adamson
1 reference
1 August 2006
1 reference
1 reference
12
1 reference
16
1 reference
4882-4887
1 reference
Identifiers
1 reference
1 reference